Catalyst
Slingshot members are tracking this event:
FDA Decision Expected in Early April for Novartis' (NVS) Marketing Application for Robociclib in HR+/HER2- Advanced Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 13, 2017
Occurred Source:
https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-lee011-receives-fda-approval-first-line-treatment
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Marketing Application, Robociclib, Hr+/her2- Advanced Breast Cancer
